1. Home
  2. SCYX

SCYX

SCYNEXIS Inc.

Logo SCYNEXIS Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Founded: 1999 Country:
United States
United States
Employees: N/A City: JERSEY CITY
Market Cap: 53.6M IPO Year: 2014
Target Price: N/A AVG Volume (30 days): 199.8K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 1.39 EPS Growth: N/A
52 Week Low/High: $1.35 - $3.87 Next Earning Date: 05-09-2024
Revenue: $140,141,000 Revenue Growth: 2652.72%
Revenue Growth (this year): -74.6% Revenue Growth (next year): -62.74%

Share on Social Networks: